Large-scale Production of Genetically Engineered CYP3A4 in E. coli: Application of a Jarfermenter

Drug Metabolism and Pharmacokinetics

Volumn 18, Issue 1, 2003, Pages 42-47

  Kanamori, Yoichi ^a   Fujita, Ken ichi ^a   Nakayama, Kazuo ^a   Kamataki, Tetsuya ^a   Kawai, Hideki ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Nihon Nosan Kogyo KK   (Japan)

Author keywords

dissolved oxygen; drug metabolism; heterologous expression; high throughput screening; pH

Indexed keywords

EID: 17644363088     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.18.42     Document Type: Article

References (22)

1. Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., Gunsalus, I. C. and Nebert, D. W.: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6: 1-42 (1996).
2. Guengerich, F. P.: Cytochrome-P450 enzymes. Am. Sci., 81: 440-447 (1993).
3. Omura, T., Ishimura, Y. and Fujii-Kuriyama, Y.: CytochromeP450 2nd ed. Tokyo, Kodansha, Inc., 1993, pp. 1.
4. Benet, L. Z., Kroetz, D. L. and Sheiner, L. B.: Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination. In Hardman, J. G., Limbird, L. E., Molinoff, P. B., Ruddon, R. W. and Gilman, A. G. (ed.): Goodman and Gilman's: The pharmacological basis of therapeutics, New York, McGraw-Hill, 1996, pp. 3-41.
5. Honig, P. K., Wortham, C., Zamani, K., Conner, D. P., Mullin, J. C. and Cantilena, L. R.: Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences. JAMA, 269: 1513-1518 (1993a).
6. Honig, P. K., Wortham, C., Zamani, K., Mullin, J. C., Conner, D. P. and Cantilena, L. R.: The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. Clin. Pharmacol. Ther., 53: 630-636 (1993b).
7. Renaud, J. P., Cullin, C., Pompon, D., Beaune, P. and Mansuy, D.: Expression of human liver cytochrome P450 IIIA4 in yeast. A functional model for the hepatic enzyme. Eur. J. Biochem., 194: 889-896 (1990).
8. Aoyama, T., Yamano, S., Guzelian, P. S., Gelboin, H. V. and Gonzalez, F. J.: Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 meta-bolically activate aflatoxin Bi. Proc. Natl. Acad. Sci. USA, 87: 4790-4793 (1990).
9. Crespi, C. L., Penman, B. W., Steimel, D. T., Gelboin, H. V. and Gonzalez, F. J.: The development of a human cell line stably expressing human CYP3A4: role in the metabolic activation of aflatoxin B1 and comparison to CYP1A2 and CYP2A3. Carcinogenesis 12: 355-359 (1991).
10. Schneider, A., Schmalix, W. A., Siruguri, V., Groene, E. M., Harbach, G. J., Kleingeist, B., Lang, D., Boker, R., Belloc, C., Beaune, P., Greim, H. and Doehmer, J.: Stable expression of human cytochrome P450 3A4 in conjunction with human NADPH-cytochrome P450 oxidoreductase in V79 Chinese hamster cells. Arch. Biochem. Biophys., 332: 295-304 (1996).
11. Buters, J. T. M., Korzekwa, K. R., Kunze, K. L., Omata, Y., Hardwick, J. P. and Gonzalez, F. J.: cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus. Drug Metab. Dispos., 22: 688-692 (1994).
12. Sakuma, T., Kitamura, R., Yokoi, T. and Kamataki, T.: Efficient complementary DNA directed expression of human fetal liver cytochrome P450 (CYP3Ain insect cells using baculovirus. Biochem. Mol. Biol. Int., 35: 447-455 (1995).
13. Barnes, H. J., Arlotto, M. F. and Waterman, M. R.: Expression and enzymatic activity of recombinant cytochrome P450 17α-hydroxylase in Escherichia coli. Proc. Natl. Acad. Sci. USA, 88: 5597-5601 (1991).
14. Gillam, E. M. J., Baba, T., Kim, B. R., Ohmori, S. and Guengerich, F. P.: Expression of modified human cytochrome P4503A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch. Biochem. Biophys., 305: 123-131 (1993).
15. Iwata, H., Fujita, K., Kushida, H., Suzuki, A., Konno, Y., Nakamura, K., Fujino, A. and Kamataki, T.: High catalytic activity of human cytochrome P450 coexpressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochem. Pharmacol., 55: 1315-1325 (1998).
16. Fujita, K. and Kamataki, T.: Genetically engineered bacterial cells co-expressing human cytochrome P450 with NADPH-cytochrome P450 reductase: Prediction of metabolism and toxicity of drugs in humans. Drug Metab. Pharmacokin., 17: 1-22 (2002).
17. Sandhu, P., Baba, T. and Guengerich, F. P.: Expression of modified cytochrome P450 2C10 (2Cin Escherichia coli, purification, and reconstitution of catalytic activity. Arch. Biochem. Biophys., 306: 443-450 (1993).
18. Omura, T. and Sato, R.: The carbon monoxide-binding pigment of liver microsomes, I. Evidence for its hemoprotein nature. J. Biol. Chem., 239: 2379-2385 (1964).
19. Phillips, A. H. and Langdon, R. G.: Hepatic triphosphopyridine nucleotide (TPN)-cytochrome c reductase: isolation, characterization, and kinetic studies. J. Biol. Chem., 237: 2652-2660 (1962).
20. Busby, W. F., Ackermann, J. M. and Crespi, C. L.: Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug. Metab. Dispos., 27: 246-249 (1998).
21. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F. P.: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270: 414-423 (1994).
22. Guengerich, F. P., Brian, W. R., Sari, M.-G. and Ross, J. T.: Expression of mammalian cytochrome P450 enzymes using Yeast-based vectors. In Waterman, M. R. and Johnson, E. F. (ed.): Methods in enzymology: Cytochrome P450 vol. 206, San Diego, Academic Press, 1991, pp. 130-145.